ByHeart Formula Botulism Litigation Consolidated as MDL-3178

The first infant botulism outbreak ever linked to commercial baby formula has become a federal mass tort. In May 2026, the Judicial Panel on Multidistrict Litigation centralized lawsuits against ByHeart, Inc. into MDL-3178 in the Southern District of New York before Judge Arun Subramanian, beginning with roughly 20 actions, according to MDL Update's May 2026 docket report. The consolidation follows an outbreak that sickened 48 infants across 19 states—every one of whom required hospitalization, the Centers for Disease Control and Prevention reported.

The litigation is moving quickly. ByHeart recalled all of its Whole Nutrition infant formula on November 11, 2025, and federal investigators later expanded the case definition back to December 2023—covering nearly the company's entire production history, NPR reported. For plaintiff firms, an MDL formed this early in a contamination event signals an intake surge built almost entirely on medical evidence.

What Triggered the Outbreak

Infant botulism is rare—the CDC typically sees 150 to 180 individual cases nationwide each year, and an outbreak of the illness is "unprecedented," the agency said in a December 2025 statement. The signal first surfaced on November 7, 2025, when California's Infant Botulism Treatment and Prevention Program (IBTPP) flagged a concerning rise in sick infants who had consumed ByHeart formula.

Within a day, the CDC and FDA were urging parents to stop using specific lots, and on November 11 ByHeart recalled all products after Clostridium botulinum was identified in the formula, the CDC's investigation page states. The disproportionate impact stood out: ByHeart represents an estimated 1% of US formula sales, yet accounted for more than 40% of formula-exposed sick infants in the outbreak, according to the FDA.

From Recall to MDL in About Six Months

The path from public health emergency to centralized litigation was unusually compressed. The timeline below traces how the outbreak escalated into a federal docket.

This kind of bounded, defined-injury docket is exactly what the JPML tends to centralize, while it has refused broader, open-ended theories in the same cycle, as Lawsuit Intelligencer's 2026 mass tort analysis noted. A single product, a single recognizable defendant, and a specific diagnosis make ByHeart a textbook candidate for coordinated pretrial proceedings.

Why This Is a Records-Intensive Docket

Infant injury cases are among the most document-heavy in mass tort, and ByHeart is no exception. Every plaintiff's file will require coordinated retrieval across several provider types:

• Pediatric and NICU/PICU records documenting the botulism diagnosis and hospital course
• Emergency department notes capturing the initial presentation, often before botulism was suspected
• BabyBIG treatment records, administered through California's IBTPP, establishing the standard-of-care intervention
• Feeding logs and pharmacy or retail purchase records tying the infant to specific ByHeart lots
• Pediatrician well-visit histories ruling out alternative causes

Because the outbreak window stretches back to 2023, many cases involve records held by multiple hospitals and health systems—sometimes in different states than where the family now lives. Firms that can pull complete, chronological neonatal and treatment records quickly will be better positioned to vet claims and meet early case-management deadlines. AI-powered retrieval and review—offered by services including LlamaLab—can identify missed treating providers and assemble Bates-referenced chronologies from high-volume pediatric files.

What Firms Should Watch Next

With MDL-3178 newly formed, the near-term sequence will mirror other product-liability dockets: a leadership structure, plaintiff fact sheets, and an early census of cases.

The Bottom Line

ByHeart's transition from a public health emergency to MDL-3178 in roughly six months underscores how fast a defined-injury contamination event can become coordinated litigation. The medical record is the backbone of every claim—from the BabyBIG treatment that defines the injury to the lot numbers that prove exposure.

For firms building intake pipelines around this docket, the practical takeaway is straightforward: comprehensive pediatric and treatment record retrieval, completed early and organized chronologically, is what separates a viable file from an incomplete one.

This article is for informational purposes only and does not constitute legal or medical advice. Sources: MDL Update, CDC Investigation, CDC Newsroom, FDA, NPR, Lawsuit Intelligencer.